Long-duration EPBD vs EST for Removal of Biliary Stones

Sponsor
Dankook University (Other)
Overall Status
Unknown status
CT.gov ID
NCT03683485
Collaborator
Inje University (Other), The Catholic University of Korea (Other), Wonkwang University (Other)
358
4
2
40
89.5
2.2

Study Details

Study Description

Brief Summary

Although EPBD has a lower risk of post-ERCP bleeding and long-term complications than EST and is easier to perform in altered/difficult anatomy, EPBD is reserved for patients with bleeding diathesis by current consensus because some studies reported a higher risk of pancreatitis. However, recent meta-analyses indicate that short EPBD duration increases the risk of post-ERCP pancreatitis, and EPBD with adequate duration has a similar pancreatitis risk and a lower overall complication rate compared with EST for choledocholithiasis.

Therefore, this study aim to compare long-duration EPBD vs EST in the treatment of extrahepatic biliary stones.

Condition or Disease Intervention/Treatment Phase
  • Procedure: long duration EPBD
  • Procedure: EST
N/A

Detailed Description

Gallstones occur in 10%-15% of adults in the United States and are the most common and costly digestive disorder. Concomitant bile duct stones occur in up to 15% of persons with symptomatic gallstones. Endoscopic retrograde cholangiopancreatography (ERCP) with sphincterotomy is the standard treatment for removal choledocholithiasis. The biliary sphincter is permanently ablated by sphincterotomy. Enteric-biliary reflux occurs with bacterial colonization, increased bile lithogenicity, contamination with cytotoxins, and chronic inflammation of the biliary system. Endoscopic papillary balloon dilation (EPBD) has become an option for removal of stones 1 cm or smaller in size. Advantages of EPBD over EST include a decreased risk of post-ERCP bleeding as well as a decreased risk of stone recurrence and cholangitis. Although a short dilation duration (≤1 minute) was previously advocated, a study that performed EPBD for 1 minute observed a 15.4% risk of post-ERCP pancreatitis with 2 cases of mortality. European Society of Gastrointestinal Endoscopy guideline recommends that the duration of EPBD should exceed 2 minutes because long-duration EPBD (>1 minute) is preferred over short-duration EPBD (≤1 minute) with better outcomes. A meta-analysis of RCTs showed that the duration of EPBD is inversely associated with the risk of PEP. Previous RCTs comparing outcome between EPBD and EST used short EPBD duration between 25 seconds and 1 minute, and there has been no comparison of outcome between EST and long-duration EPBD. The aim of this study was to compare the early and long term outcomes of patients treated with long duration balloon dilation or sphincterotomy for extraction of bile duct stones in a randomized, multicenter fashion involving a broad spectrum of practices.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
358 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Long-duration (3 Minutes) Endoscopic Papillary Balloon Dilation Versus Endoscopic Sphincterotomy in Patients With a Naive Major Papilla and Small- to Medium Sized Biliary Stones: Multicenter, Randomized, Controlled Trial
Actual Study Start Date :
Apr 1, 2018
Anticipated Primary Completion Date :
May 1, 2019
Anticipated Study Completion Date :
Aug 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: long duration EPBD group

Balloon dilation was performed using wire-guided hydrostatic balloon catheters. An 8-mm dilatation balloon was used for EPBD. Balloons were gradually inflated to maximum pressure for 3 minute, and complete inflation was verified by fluoroscopy. Stones were removed by standard techniques, including balloon or basket catheters.

Procedure: long duration EPBD
An 8-mm dilatation balloon was used for EPBD. Balloons were gradually inflated to maximum pressure for 3 minute, and complete inflation was verified by fluoroscopy.

Procedure: EST
After deep cannulation was achieved, a complete sphincterotomy was performed with a 25-mm pull-type sphincterotome (Clever Cut 3; KD-V411M, Olympus, Tokyo, Japan) and the sphincter was divided up to the transverse duodenal fold.

Active Comparator: endoscopic sphincterotomy (EST) group

After deep cannulation was achieved, a complete sphincterotomy was performed with a 25-mm pull-type sphincterotome (Clever Cut 3; KD-V411M, Olympus, Tokyo, Japan) and the sphincter was divided up to the transverse duodenal fold. A complete sphincterotomy was defined by the free passage of a fully bowed sphincterotome and the presence of spontaneous bile drainage. A complete sphincterotomy was defined by the free passage of a fully bowed sphincterotome and the presence of spontaneous bile drainage.

Procedure: long duration EPBD
An 8-mm dilatation balloon was used for EPBD. Balloons were gradually inflated to maximum pressure for 3 minute, and complete inflation was verified by fluoroscopy.

Procedure: EST
After deep cannulation was achieved, a complete sphincterotomy was performed with a 25-mm pull-type sphincterotome (Clever Cut 3; KD-V411M, Olympus, Tokyo, Japan) and the sphincter was divided up to the transverse duodenal fold.

Outcome Measures

Primary Outcome Measures

  1. rate of adverse event [up to 1 month after ERCP]

    Number of participants with treatment-related adverse events

Secondary Outcome Measures

  1. the stone clearance rate at the index ERCP [during ERCP]

    complete extraction of choledocholithiasis of all stones, fragments, and sludge at the initial procedure

  2. direct cost [within 30 day after ERCP]

    The direct cost included the total cost for the entire admission, which comprised costs of hospital stay, performed procedures, and management of complications

  3. recurrence of choledocholithiasis [more than 3 year follow-up]

    recurrent choledocholithiasis or acute cholangitis either with or without bile duct stones, and overall hepatobiliary complications

  4. adverse event (pancreatitis) [up to 1 month after ERCP]

    rate of pancreatitis

  5. adverse event (bleeding) [up to 1 month after ERCP]

    rate of bleeding

  6. adverse event (cholangitis) [up to 1 month after ERCP]

    rate of cholangitis

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Consecutive patients were invited to participate by the investigators or research staff if they were at least 18 years old,

  • patients who had known or suspected choledocholithiasis

Exclusion Criteria:
  • active acute pancreatitis

  • septic shock,

  • coagulopathy (international normalized ratio >1.2, partial thromboplastic time greater than twice that of control),

  • platelet count <50,000 x 103/uL,

  • anticoagulation therapy within 48 hours of the procedure,

  • stone diameter > 8 mm,

  • bile duct diameter >15 mm, prior sphincterotomy,

  • need for precut sphincterotomy for biliary access,

  • biliary stricture,

  • Billroth II or Roux-en-Y anatomy,

  • periampullary malignancies,

  • primary sclerosing cholangitis, pregnancy,

  • and inability to give informed consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 Dankook University College of Medicine Cheonan Chungcheongnam-do Korea, Republic of 330-715
2 Wonkwang University Iksan Jeollabukdo Korea, Republic of
3 Inje University, Haeundae Paik Hospital Busan Korea, Republic of
4 St. Mary's Hospital, The Catholic University of Korea, Daejeon Korea, Republic of

Sponsors and Collaborators

  • Dankook University
  • Inje University
  • The Catholic University of Korea
  • Wonkwang University

Investigators

  • Principal Investigator: Jun Ho Choi, MD, PhD, Dankook University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jun Ho Choi, Assistant Professor, Dankook University
ClinicalTrials.gov Identifier:
NCT03683485
Other Study ID Numbers:
  • 2018-03-009
First Posted:
Sep 25, 2018
Last Update Posted:
Oct 1, 2018
Last Verified:
Sep 1, 2018
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Jun Ho Choi, Assistant Professor, Dankook University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 1, 2018